Modality
mAb
MOA
CD47i
Target
PRMT5
Pathway
Incretin
CeliacCervical CaPBC
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
~Apr 2021
→ ~Jul 2022
Phase 2
Oct 2022
→ Jul 2030
Phase 2Current
NCT07724336
800 pts·Cervical Ca
2022-10→TBD·Recruiting
NCT06662471
813 pts·Celiac
2023-04→2030-07·Recruiting
1,613 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-174.3y awayPh2 Data· Celiac
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2030-07-17 · 4.3y away
Celiac
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07724336 | Phase 2 | Cervical Ca | Recruiting | 800 | LiverFat |
| NCT06662471 | Phase 2 | Celiac | Recruiting | 813 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Suracagene | GSK | Phase 3 | PRMT5 |